Life log technology, Inc. announced that it has received ¥170 million in funding from Shin Nippon Biomedical Laboratories, Ltd., Advantage Risk Management Co., Ltd., TIS Inc., DG Daiwa Ventures
July 01, 2019
Share
Life log technology, Inc. announced that it has received ¥170 million in a round of funding on July 2, 2019. The transaction included participation from Advantage Risk Management Co., Ltd. (TSE:8769), TIS Inc. (TSE:3626), Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), and existing investor, DG Lab No. 1 Fund, a fund managed by DG Daiwa Ventures.
The transaction is by way of third party capital increase in the company. As part of the transaction, Advantage Risk Management Co., Ltd., TIS Inc., and Shin Nippon Biomedical Laboratories, Ltd conclude a capital tie up with the company.
Advantage Risk Management Co Ltd is a Japan-based company mainly engaged in the mental disability support activities, group long-term disability compensation insurance, and risk finance business. The Company operates through three segments. The Mental Health Care segment is engaged in the provision of mental health care services ranging from stress checks to counseling, organizational analysis, subsequent solutions, and aptitude tests for recruitment based on stress tolerance and emotional intelligence (EQ). The Employment Disability Support segment is engaged in the provision of comprehensive services related to Group Long-Term Disability (GLTD) insurance, offering sales of insurance products and professional know-how and supplementary services including system design, proposals, consulting and support for returning to work. The Risk Financing segment sells individual insurance products, such as cancer insurance, mainly to individuals working for companies and other organizations.
Life log technology, Inc. announced that it has received ¥170 million in funding from Shin Nippon Biomedical Laboratories, Ltd., Advantage Risk Management Co., Ltd., TIS Inc., DG Daiwa Ventures